Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod in House Dust Mite Allergic Rhinoconjunctivitis
NCT00800332Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Nov 2008
- Primary completion
- Apr 2010
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 6
01
Overview
A Phase 2 trial of vidutolimod in allergic rhinoconjunctivitis (ARC), sponsored by Cytos Biotechnology AG. Started Nov 2008; status: completed.
02
Drugs
vidutolimod
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00800332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800332.